Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry

Li, Jinong, Orlandi, Rosaria, White, C Nicole, Rosenzweig, Jason, Zhao, Jing, Seregni, Ettore, Morelli, Daniele, Yu, Yinhua, Meng, Xiao-Ying, Zhang, Zhen, Davidson, Nancy E, Fung, Eric T, Chan, Daniel W · 2005 · Clinical Chemistry

Abstract

Background: We previously selected a panel of 3 breast cancer biomarkers (BC1, BC2, and BC3) from serum samples collected at a single hospital based on their collective contribution to the optimal separation of breast cancer patients and noncancer controls by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The identities and general applicability of these markers, however, were unknown. In this study, we performed protein expression profiling on samples obtained from a second hospital, included a greater number of ductal carcinoma in situ (DCIS) cases, and performed purification and identification of the 2 confirmed markers. Methods: Using a case–control study design, we performed protein expression profiling on serum samples from the National Cancer Institute (Milan, Italy). The validation sample cohort consisted of 61 women with locally invasive breast cancer, 32 with DCIS, 37 with various benign breast diseases (including 13 atypical), and 46 age-matched apparently healthy women (age range, 44–68 years). Validated biomarkers were purified and identified with serial chromatography, 1-dimensional gel electrophoresis, in-gel ASP-N digestion, peptide mass fingerprinting, and tandem mass peptide sequencing. Results: The BC3 and BC2 expression patterns in this sample set were consistent with the first study sample set. BC3 and BC2 were identified to be complement component C3adesArg and a C-terminal–truncated form of C3adesArg, respectively. Conclusions: Evaluation of biomarkers in independent sample sets can help determine the broader utility of candidate markers, and protein identification permits understanding of their molecular basis. C3adesArg appears to lack specificity among patients with benign diseases, limiting its utility as a stand-alone tumor marker, but it may still be useful in a multimarker panel for early detection of breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2005.052878

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 183

Metadata

Authors
Li, J., Orlandi, R., White, C. N., Rosenzweig, J., Zhao, J., Seregni, E., Morelli, D., Yu, Y., Meng, X.-Y., Zhang, Z., Davidson, N. E., Fung, E. T., & Chan, D. W.
Venue
Clinical Chemistry
Published
2005-12-01
Volume
51
Issue
12
Pages
2229-2235
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2168444314
Cited by
183
References
1
FWCI
10.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. https://app.cochat.ai/papers/10.1373/clinchem.2005.052878
The paper
Li, J., Orlandi, R., White, C. N., Rosenzweig, J., Zhao, J., Seregni, E., Morelli, D., Yu, Y., Meng, X.-Y., Zhang, Z., Davidson, N. E., Fung, E. T., & Chan, D. W. (2005). Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. Clinical Chemistry. https://doi.org/10.1373/clinchem.2005.052878

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.